{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127099","form_type":"8-K","ticker":null,"cik":"0001834645","company_name":"Peak Bio, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.921916+00:00","generated_at":"2026-05-30T00:35:49.080527+00:00","sec_items":["2.01","3.02","3.03","5.01","5.02","5.03","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Peak Bio completes merger with Akari; exchange ratio 0.2935, 48.4% ownership","bullets":["Each Peak Bio share converted into 0.2935 Akari ADS; Peak stockholders own ~48.4% of combined company.","Outstanding convertible notes with $8.4M principal converted into 19.4M Peak Bio shares pre-merger.","Concurrent private placement of 1.71M Akari ADS and warrants raises $3.2M gross proceeds.","All prior directors resigned; Samir R. Patel appointed President and Secretary post-merger.","Peak Bio becomes wholly-owned subsidiary of Akari; charter and bylaws amended."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127099","json":"https://secwatch.observer/filing/0000950170-24-127099.json","markdown":"https://secwatch.observer/filing/0000950170-24-127099.md","text":"https://secwatch.observer/filing/0000950170-24-127099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/pkbo-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:35:49.080527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48df50f22e","claim":"James Neal resigned as Director at Peak Bio, Inc..","evidence_excerpt":"Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4a1a8a6e15","claim":"Samir R. Patel was appointed as President and Secretary at Peak Bio, Inc..","evidence_excerpt":"Samir R. Patel, M.D. was appointed to serve as President and Secretary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Secretary"}],"fact_type":"executive_change"},{"claim_id":"7345f67437","claim":"Hoyoung Huh resigned as Director at Peak Bio, Inc..","evidence_excerpt":"Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d9f5747bf7","claim":"Sandip Patel resigned as Director at Peak Bio, Inc..","evidence_excerpt":"Hoyoung Huh, MD, PhD, James Neal and Sandip Patel resigned as directors of the Company and any committees thereof.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"139f028b97bd845a3f2004d6fa686514be917013","claim":"Peak Bio, Inc. underwent a change of control involving Akari Therapeutics, Plc (closed 2024-11-14).","evidence_excerpt":"On November 14, 2024, Peak Bio Inc. (the “Company”) completed the previously announced strategic combination (the “Closing”) contemplated by the Agreement and Plan of Merger by and among the Company, Akari Therapeutics, Plc, a public company limited by shares under the laws of England and Wales (“Akari”) and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”), as amended by that certain side letter dated August 15, 2024 (the “Merger Agreement”), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of Akari.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1834645/000095017024127099/0000950170-24-127099-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Akari Therapeutics, Plc"},{"label":"Closing","value":"2024-11-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}